Affinity Asset Advisors, LLC 13F holdings, Q4 2025
Holdings as of December 31, 2025 · filings on SEC EDGAR · latest filing →
Affinity Asset Advisors, LLC disclosed 86 US equity positions worth $1.4bn in its Q4 2025 13F filing. The largest position was APGE at 6.7% of the reported book, followed by INSM and ABVX. Against the Q3 2025 filing, it opened 9 new positions, added to 20 and reduced 14 among the top 50 holdings.
What did Affinity Asset Advisors, LLC own in Q4 2025? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2025 |
|---|---|---|---|---|---|---|---|
| 1 | APGE APOGEE THERAPEUTICS INC | Healthcare | 6.7% | $93.2m | 1,234,926 | 5% | added |
| 2 | INSM INSMED INC | Healthcare | 5.6% | $78.3m | 450,000 | 0% | held |
| 3 | ABVX ABIVAX SA | 4.9% | $68.1m | 505,000 | 40% | added | |
| 4 | VTYXUSD VENTYX BIOSCIENCES INC | 4.2% | $58.6m | 6,484,558 | 65% | added | |
| 5 | XENE XENON PHARMACEUTICALS INC | Healthcare | 4.0% | $56.0m | 1,250,000 | -11% | reduced |
| 6 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 3.9% | $54.5m | 185,000 | – | new |
| 7 | CYTK CYTOKINETICS INC | Healthcare | 3.7% | $50.8m | 800,000 | 129% | added |
| 8 | SYRE SPYRE THERAPEUTICS INC | 3.4% | $46.9m | 1,432,591 | 1% | added | |
| 9 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 3.3% | $45.9m | 2,700,000 | 29% | added |
| 10 | TEVA TEVA PHARMACEUTICAL INDS LTD | Healthcare | 3.1% | $43.7m | 1,400,000 | 0% | held |
| 11 | ROIV ROIVANT SCIENCES LTD | Healthcare | 2.7% | $36.9m | 1,700,000 | 112% | added |
| 12 | ACLXGBX ARCELLX INC | 2.5% | $34.1m | 523,725 | 5% | added | |
| 13 | NUVALENT INC | 2.3% | $32.5m | 322,633 | -16% | reduced | |
| 14 | LXEO LEXEO THERAPEUTICS INC | Healthcare | 2.3% | $31.8m | 3,200,000 | -17% | reduced |
| 15 | ALKS ALKERMES PLC | Healthcare | 2.0% | $28.0m | 1,000,000 | -20% | reduced |
| 16 | FBRX FORTE BIOSCIENCES INC | 1.9% | $27.0m | 989,490 | – | new | |
| 17 | TRVI TREVI THERAPEUTICS INC | Healthcare | 1.9% | $26.9m | 2,150,172 | -23% | reduced |
| 18 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 1.9% | $26.5m | 730,000 | -3% | reduced |
| 19 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 1.8% | $24.5m | 320,000 | 392% | added |
| 20 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 1.7% | $24.3m | 802,342 | -16% | reduced |
| 21 | 430 TERNS PHARMACEUTICALS INC | 1.6% | $22.2m | 550,000 | – | new | |
| 22 | ANAB ANAPTYSBIO INC | Healthcare | 1.5% | $21.6m | 444,692 | – | new |
| 23 | CGEM CULLINAN THERAPEUTICS INC | Healthcare | 1.4% | $20.0m | 1,932,106 | 632% | added |
| 24 | OMEROS CORP | 1.4% | $19.4m | 6,525,000 | 18% | added | |
| 25 | AVTX AVALO THERAPEUTICS INC | Healthcare | 1.4% | $19.1m | 1,051,054 | 4% | added |
| 26 | NRIX NURIX THERAPEUTICS INC | Healthcare | 1.3% | $18.4m | 967,620 | 0% | held |
| 27 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 1.3% | $18.1m | 3,300,000 | 10% | added |
| 28 | MDGL MADRIGAL PHARMACEUTICALS INC | Healthcare | 1.3% | $18.1m | 31,131 | -73% | reduced |
| 29 | SVRA SAVARA INC | Healthcare | 1.2% | $16.9m | 2,797,153 | 86% | added |
| 30 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 1.1% | $15.0m | 172,125 | -22% | reduced |
| 31 | CNTA CENTESSA PHARMACEUTICALS PLC | 1.1% | $15.0m | 600,552 | -46% | reduced | |
| 32 | ESTA ESTABLISHMENT LABS HLDGS INC | Healthcare | 1.0% | $14.6m | 200,000 | -35% | reduced |
| 33 | ERAS ERASCA INC | Healthcare | 1.0% | $14.5m | 3,900,000 | -9% | reduced |
| 34 | VERA VERA THERAPEUTICS INC | Healthcare | 0.9% | $12.7m | 250,000 | -18% | reduced |
| 35 | COGT COGENT BIOSCIENCES INC | Healthcare | 0.9% | $12.4m | 350,000 | – | new |
| 36 | OVID OVID THERAPEUTICS INC | Healthcare | 0.8% | $11.7m | 7,150,000 | 170% | added |
| 37 | TVTX TRAVERE THERAPEUTICS INC | Healthcare | 0.8% | $11.5m | 300,000 | -40% | reduced |
| 38 | JBIO JADE BIOSCIENCES INC | 0.8% | $11.0m | 714,956 | 995% | added | |
| 39 | TVTX TRAVERE THERAPEUTICS INC | 0.7% | $10.0m | 7,000,000 | 0% | held | |
| 40 | NEWAMSTERDAM PHARMA COMPANY | 0.7% | $9.6m | 275,000 | 0% | held | |
| 41 | CLDX CELLDEX THERAPEUTICS INC NEW | Healthcare | 0.7% | $9.5m | 350,000 | 17% | added |
| 42 | ZURA ZURA BIO LTD | Healthcare | 0.7% | $9.5m | 1,813,671 | 42% | added |
| 43 | TNGX TANGO THERAPEUTICS INC | Healthcare | 0.6% | $8.9m | 1,000,000 | – | new |
| 44 | STRO SUTRO BIOPHARMA INC | Healthcare | 0.6% | $8.7m | 748,382 | – | new |
| 45 | RVMD REVOLUTION MEDICINES INC | Healthcare | 0.6% | $8.0m | 100,000 | 0% | held |
| 46 | MBX MBX BIOSCIENCES INC | Healthcare | 0.6% | $7.9m | 250,000 | 52% | added |
| 47 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 0.6% | $7.8m | 250,000 | 0% | held |
| 48 | RCUS ARCUS BIOSCIENCES INC | Healthcare | 0.5% | $7.1m | 300,000 | – | new |
| 49 | SGMT SAGIMET BIOSCIENCES INC | Healthcare | 0.5% | $6.8m | 1,148,245 | 228% | added |
| 50 | KPTI KARYOPHARM THERAPEUTICS INC | 0.5% | $6.5m | 889,575 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.